Momentum Biotechnologies has partnered with Cube Biotech to support clients with new therapeutic solutions.
The collaboration will bolster the development of new therapeutic solutions by combining Cube Biotech’s protein technology platforms with Momentum’s expertise in identifying and developing clinical leads.
Cube’s protein technology platforms are designed to allow difficult membrane proteins to be synthesised and purified without native structure compromise.
The partnership is set to provide advanced high-throughput methods to clients for investigating membrane-bound proteins.
Momentum Biotechnologies founder and CEO Can Ozbal stated: “Our premier screening capabilities provide the perfect complement to Cube’s innovative protein technologies.
“This partnership will ultimately allow our clients to identify and optimise hits even more effectively, supporting the development of cutting-edge therapeutics.”
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Momentum Biotechnologies provides a range of services to its biopharmaceutical clients, including affinity-selection mass spectrometry (ASMS), chemoproteomics, covalent binding assays and small-molecule analysis.
These services are critical in the drug discovery process, helping to accelerate the identification, validation, and characterisation of therapeutic leads.
Cube Biotech’s platform, NativeMP, allows the study of complex membrane proteins under native conditions, avoiding harsh detergents.
Cube Biotech co-founder and chief scientific officer Jan Kubicek stated: “By combining our strengths with Momentum Biotechnologies’ offerings, we aim to break new ground in drug discovery and accelerate the development of innovative therapies.
“Our complementary technologies and shared dedication to scientific excellence will significantly enhance our ability to tackle the most challenging protein targets and deliver actionable insights to our clients.”
